908 Devices Inc.
MASSHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframe908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. Valued at $318.0M, MASS is a small-cap name in its sector. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample.
Market Cap
$318.0M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-29.34
EPS (TTM)
$-0.97
EPS (Fwd)
$-0.29
ROE
-24.1%
ROA
-7.6%
Cash
$111.7M
Total Debt
$4.5M
Free CF
$13.7M
52W Change
41.3%
Annual Financials
Cash vs Debt
908 Devices Inc. holds $111.7M in cash against $4.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $13.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -24.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $46.9M to $56.2M.
The relatively low beta of 0.56 suggests MASS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing MASS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.